Biovica wins SEK 1 million oncology study work order from global pharma customer

Silvercorp Metals Inc.
Rentokil Initial plc Sponsored ADR

Silvercorp Metals Inc.

SVM

0.00

Rentokil Initial plc Sponsored ADR

RTO

0.00
  • Biovica received its first work order under an expanded Master Services Agreement with a leading global pharmaceutical customer.
  • Order covers DiviTum TKa testing for a new oncology clinical study, with patient visits expected to start in September 2026.
  • Work will run about two years through Biovica’s CLIA-certified laboratory in San Diego.
  • Order value is about SEK 1 million, covering sample testing and related laboratory services.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.